pravastatin has been researched along with Cerebrovascular Disorders in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (68.18) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Kakinoki, S; Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Afonso, L; Arora, N; Bhattacharya, P; Ference, BA; Madhavan, R; Mahajan, N; Sacks, F; Sagar, A; Sudhakar, R; Wang, Y | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Koizumi, J; Mabuchi, H; Miyamoto, S; Origasa, H; Shimizu, M | 1 |
| Shepherd, J | 1 |
| Blauw, GJ; Bollen, EL; Buckley, BM; Cobbe, SM; DE Craen, AJ; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Macfarlane, PW; Murphy, MB; Norrie, J; Packard, CJ; Perry, IJ; Pons, D; Shepherd, J; Slagboom, P; Stott, DJ; Sweeney, BJ; Trompet, S; Twomey, C; Westendorp, RG | 1 |
| Bellandi, F; Cantini, F; Palchetti, R; Pedone, T | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Stiffman, MN | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
| Henry, RY; Kendall, MJ | 2 |
| Furberg, CD | 1 |
| Bernstein, V; Braunwald, E; Cuddy, TE; Davis, BR; Moyé, LA; Pfeffer, MA; Piller, LB; Plehn, JF; Rouleau, JL; Rutherford, J; Sacks, FM; Simpson, LM | 1 |
4 review(s) available for pravastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Does cholesterol lowering prevent stroke?
Topics: Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Diagnostic Imaging; Humans; Hypercholesterolemia; Meta-Analysis as Topic; Multicenter Studies as Topic; Pravastatin; Risk Factors | 1998 |
8 trial(s) available for pravastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia.
Topics: Adult; Aged; Blood Pressure; Cerebrovascular Disorders; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Prospective Studies | 2012 |
Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction.
Topics: Aged; Cerebrovascular Disorders; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Risk Factors; Triglycerides | 2012 |
Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Topics: Adult; Aged; Anticholesteremic Agents; Cerebrovascular Disorders; Cholesterol, LDL; Coronary Disease; Female; Humans; Japan; Male; Middle Aged; Pravastatin; Treatment Outcome | 2002 |
Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study.
Topics: Aged; Cerebrovascular Disorders; Female; Genetic Variation; Haplotypes; Humans; Interleukin-10; Male; Middle Aged; Models, Biological; Polymorphism, Single Nucleotide; Pravastatin; Promoter Regions, Genetic; Risk; Risk Factors | 2007 |
[Cholesterol and vascular disease. Study of pravastatin ].
Topics: Adult; Aged; Cerebrovascular Disorders; Coronary Disease; Drug Evaluation; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin | 1993 |
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Risk; Scotland | 1996 |
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Topics: Aged; Animals; Anticholesteremic Agents; Cats; Cerebrovascular Disorders; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Treatment Outcome; Triglycerides | 1999 |
Clinical trials in stroke.
Topics: Cerebrovascular Disorders; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Risk; Treatment Outcome | 1999 |
10 other study(ies) available for pravastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Preventing the next event in the elderly: the PROSPER perspective.
Topics: Aged; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
Topics: Cerebrovascular Disorders; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Mortality; Pravastatin; Simvastatin | 1997 |
"Statin" drugs, mortality, and stroke prevention.
Topics: Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Meta-Analysis as Topic; Mortality; Pravastatin; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin | 1997 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |
Natural statins and stroke risk.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Myocardial Infarction; Pravastatin; Simvastatin | 1999 |
Pravastatin for reducing stroke risk.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Pravastatin | 1999 |
Pravastatin shown to reduce stroke risk after heart attacks.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Humans; Myocardial Infarction; Pravastatin | 1999 |